Experimental CAR-T therapy takes aim at Hard-to-Treat myeloma
NCT ID NCT07234721
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new cell therapy called SL4903 for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified to better attack the cancer. The main goal is to check safety and find the right dose in a small group of 9 to 18 adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SL4903 CAR-T cells (a type of immune cell therapy)
- What this could lead to
- If it works, this could point toward a new treatment option for multiple myeloma that has stopped responding to standard therapies.
- What could go wrong
- This is a very early, small trial (9-18 people) focused on safety, not proof of effectiveness. Side effects like cytokine release syndrome and neurotoxicity are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.